Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: Its efficacy and problems

Neurological Research

Volumn 18, Issue 4, 1996, Pages 342-344

  Asada, M ^a   Kong, J ^a   Nakamura, M ^a   Tamaki, N ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Subarachnoid hemorrhage; tissue plasminogen activator; vasospasm

Indexed keywords

ALTEPLASE; SILTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; BRAIN VASOSPASM; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; INTRATHECAL DRUG ADMINISTRATION; RABBIT; SUBARACHNOID HEMORRHAGE;

EID: 0029743496     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1080/01616412.1996.11740433     Document Type: Conference Paper

References (12)

1. Findlay JM, Weir BKA, Steinke D et al. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH. J Neurosur 1988; 69: 723-735
2. Findlay JM, Weir BKA, Gordon P, et al. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm. Neurosurgery 1989; 24: 491-498
3. Seifert V, Eisert WG, Stoke D, et al. Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 1989; 25: 590-598
4. Findlay JM, Weir BKA, Kassell NF, et al. Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage. J Neurosurg 1991; 75: 181-188
5. Zabramski JM, Spetzler RF, Lee KS, et al. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1991; 75: 189-196.
6. Ohmen J, Servo A, Heiskanen O. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1991; 75: 197-201
7. Mizoi K, Yoshimoto T, Takahashi A, et al. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator. J Neurosurg 1993; 78: 430-437
8. Sasaki T, Ohta T, Kikuchi H, et al. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 1994; 35: 597-605
9. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: Relevance for the success of therapy. Circulation 1991; 83: 937-944.
10. Asada M, Ishida K, Tamaki N, et al. Preventive action of cisternal heparin injection for vasoconstriction after experimental subarachnoid hemorrhage. Suzuki J, ed. Advances in Surgery for Cerebral Stroke, Heidelberg: Springer-Verlag, 1987: pp. 705-709
11. Asada M, Yang, YS, Fujita K. et al. Role of antithrombin III in vasoconstriction after experimental subarachnoid hemorrhage. Sano K, ed. Cerebral Vasospasm, University of Tokyo Press, 1990: pp. 409-410
12. Asada M, Kong J, Nakamura M, et al. Combination therapy with tissue plasminogen activator and antithrombin III in experimental vasospasm. In: Findlay JM, ed. Cerebral Vasospasm, Amsterdam: Elsevier, 1993: pp. 487-490